BioCentury

8:00 AM GMT, Dec 5, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Deals

Exelixis deal

Exelixis partnered with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for the clinical development of Exelixis' cabozantinib in several

Read the full 210 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.